

S9 Supporting Information. Summary of the sensitivity analysis of the best-evidence synthesis for *BRCA1* (panel A), *BRCA2* (panel B) and *BRCA1/2* (panel C) mutation carriership and breast cancer prognosis.

Sensitivity analyses are performed by changing the cut-offs for an effect and using only the significant results (still only the HQ studies are used for the best evidence synthesis).

A. Sensitivity analysis of the best-evidence synthesis: *BRCA1* mutation carriership

		Survival	Evidence ^b based on HQ studies			
Type of survival	Unadjusted/ adjusted ^a	Better: Worse:	Original cut-offs:			p < 0.05
			>=5% / HR <=0.94 >=5% / HR >=1.07	>=10% / HR <=0.88 >=10% / HR >=1.14	>=15% / HR <=0.82 >=15% / HR >=1.22	
Overall	Unadjusted		Indecisive	Indecisive	Nil	Nil
	Adjusted		Moderate	Indecisive	Indecisive	Nil
BC-specific	Unadjusted		Moderate	Indecisive	Indecisive	Nil
	Adjusted		Indecisive	Indecisive	Nil	Nil
Metastasis-free	Unadjusted		Indecisive	Indecisive	Indecisive	Indecisive
	Adjusted		Indecisive	Indecisive	Indecisive	Nil
Recurrence-free	Unadjusted		Moderate	Moderate	Moderate	Nil
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*

B. Sensitivity analysis of the best-evidence synthesis: *BRCA2* mutation carriership

		Survival	Evidence ^b based on HQ studies			
Type of survival	Unadjusted/ adjusted ^a	Better: Worse:	Original cut-offs:			p < 0.05
			>=5% / HR <=0.94 >=5% / HR >=1.07	>=10% / HR <=0.88 >=10% / HR >=1.14	>=15% / HR <=0.82 >=15% / HR >=1.22	
Overall	Unadjusted		Moderate	Indecisive	Nil	Nil
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
BC-specific	Unadjusted		Indecisive	Indecisive	Moderate	Nil
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
Metastasis-free	Unadjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
Recurrence-free	Unadjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*

C. Sensitivity analysis of the best-evidence synthesis: *BRCA1/2* mutation carriership

		Survival	Evidence ^b based on HQ studies			
Type of survival	Unadjusted/ adjusted ^a	Better: Worse:	Original cut-offs:			p < 0.05
			>=5% / HR <=0.94 >=5% / HR >=1.07	>=10% / HR <=0.88 >=10% / HR >=1.14	>=15% / HR <=0.82 >=15% / HR >=1.22	
Overall	Unadjusted		Nil	Nil	Nil	Nil
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
BC-specific	Unadjusted		Indecisive	Indecisive	Indecisive	Moderate
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
Metastasis-free	Unadjusted		Indecisive	Indecisive	Indecisive	Indecisive
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*
Recurrence-free	Unadjusted		Indecisive	Indecisive	Nil	Nil
	Adjusted		Indecisive*	Indecisive*	Indecisive*	Indecisive*

^aAdjusted survival is based on risk estimates adjusted for clinico-pathological characteristics and/or treatment;

^bSee S2 Supporting Information (Best-evidence synthesis). Strong evidence: more than 75% of the HQ studies reported a worse survival; moderate evidence: 60-75% of the HQ studies reported a worse survival and less than 25% of the HQ studies reported a better survival / 50-60% of the HQ studies reported a worse survival and less than 10% of the HQ studies reported a better survival; nil evidence: more than 60% of the HQ studies reported a better survival or no association / more than 40% of the HQ studies reported a better survival; indecisive evidence: all other options / less than four HQ studies available (*).